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2Abstract
Purpose of the review
To evaluate the potential clinical utility of amyloid imaging.
Recent findings
Amyloid PET is a valid in vivo marker of neuritic plaque load and correlates with amyloid plaque surface
area. Abundant diffuse plaques, however, with scant neuritic plaques can also give rise to a positive scan,
most often reported in association with Lewy body disease. Specificity of amyloid PET for discriminating
AD from healthy controls is higher than that of structural MRI. Sensitivity for discriminating AD from
healthy controls or from FTLD is also higher than that of fluorodeoxyglucose-PET, with higher interreader
reliability. Within a same centre there is high concordance between dichomization of cases based on
amyloid PET versus cerebrospinal fluid Aβ42. In a tentative algorithm, we restrict clinical-diagnostic use
to dementia with age of onset before 60 years, primary progressive aphasia and corticobasal syndrome,
cases with objective cognitive deficits that could be due to a neurodegenerative cause but also have
significant cerebrovascular or psychiatric comorbidity, and rapidly progressive dementia.
Summary
Empirical studies how amyloid PET can change clinical-diagnostic thinking are starting to emerge. Key
questions to be resolved are its role compared to cerebrospinal fluid markers and its impact on patient
outcome.
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31 Introduction
Our confidence in the accuracy of a diagnosis of clinically probable Alzheimer’s disease is mainly founded
on clinicopathological series with the neuropathological diagnosis as standard-of-truth. A neuropatholog-
ical diagnosis of Alzheimer’s (AD) [1] relies on the amount of neuritic plaques in prespecified regions [2]
and the topographical spread of neuritic and diffuse amyloid plaques [3] and neurofibrillary tangles [4].
In a multicenter academic memory clinic series, the positive predictive value of a diagnosis of clinically
probable AD for the presence of a moderate to severe amount of neuritic amyloid plaques and neurofibril-
lary tangles fulfilling Braak stage 3-6 was 83%, with a sensitivity and specificity of 71% [5**]. Inversely,
when the clinical premortem diagnosis was a non-AD dementia, more than one third nevertheless met or
exceeded minimum threshold levels for AD histopathology [5**]. A diagnosis of possible AD had an even
lower positive predictive value [5**]. Improving diagnostic accuracy is an important goal in possible AD,
but clearly there remains room for diagnostic improvement in clinically probable AD too. Conceivably,
our diagnostic accuracy at the time of diagnosis and during the initial years of follow-up will be even
lower than what the neuropathological series suggests. The same goes for predementia compared to the
dementia stage.
The goal of this review is to address whether and how amyloid positron emission tomography (PET)
imaging can enhance early diagnostic accuracy of possible and probable AD. One of the first requirements
for clinical utility of a novel diagnostic technique is that it either improves diagnostic accuracy over and
above standard clinical procedures or (partly) replaces current diagnostic procedures with comparable
accuracy in a cost-effective manner. The current review will focus principally on the gain in diagnostic
accuracy that amyloid imaging may permit under well-defined circumstances in clinical practice. Empirical
evidence on how this affects patient management and outcome is still limited at the moment. The
importance of amyloid scanning in a clinical research context (e.g. therapeutic trials) is also beyond the
scope of this review.
At the time of writing, only 18F-florbetapir has received regulatory approval for clinical use for detec-
tion of neuritic plaque load in patients with objective cognitive deficits in whom a diagnosis of Alzheimer’s
disease is considered.
2 Consistency within and between amyloid imaging modalities
The amyloid PET tracers developed to date belong to various chemical classes. According to a post-
mortem study of homogenized brain tissue in AD and controls, thioflavine T derivatives (such as 11C-
Pittsburgh compound B (PIB) and its derivative 18F-flutemetamol), stilbenes (18F-florbetapir and 18F-
florbetaben, among others), and benzofuranes (18F-NAV4694) share a common high-affinity binding site
that explains most of the signal in AD [6**]. The majority of the currently available 18F-ligands has been
compared in vivo to 11C-PIB (Table 1): Neocortical values for retention of 18F-amyloid ligands correlate
well with neocortical values of retention of 11C-PIB. For 18F-florbetapir [7, 8], the regression slope is
less steep than for other ligands, suggesting a smaller dynamic range (Table 1). For the 18F-ligands in
general, correlation in subcortical white matter is much lower, and only NAV4694 has a high correlation
value with 11C-PIB also in white matter [9**] (Table 1).
Test-retest values (% difference between two time points divided by the average obtained at the two
time points) of Standardized Uptake Value Ratios (SUVR) for a composite cortical volume of interest
418F-flutemetamol 18F-florbetapir 18F-florbetaben 18F-NAV4694
r m r m r m r m
Composite 0.91 0.99 0.78 0.33 0.97 0.71 0.99 0.95
0.86-0.95 0.59-0.64
Frontal 0.92 1.00 0.81 - 0.94-0.96 - 0.95-0.99 -
Parietal 0.92 1.01 0.58 - 0.94 - 0.97 -
Lateral temporal 0.91 0.99 0.68 - 0.96 - 0.99 -
Posterior cingulate 0.91 1.01 0.79 - 0.96 - 0.99 -
Anterior cingulate 0.88 0.91 0.81 - 0.94 - 0.98 -
Medial temporal 0.83 0.74 - - 0.82 - 0.95 -
Occipital 0.89 1.03 - - 0.92 - 0.96 -
Striatum 0.84 0.88 - - 0.95 - 0.98 -
Subcortical white matter 0.22 0.36 - - 0.63 - 0.79 -
Pons 0.63 0.50 0.38 - 0.50 - 0.87 -
Table 1: Correlations between amyloid ligands. Within-subject correlations between SUVR for 11C-PIB and 
18F-flutemetamol (20 AD, 20 MCI) [10],  18F-florbetapir  (14 AD, 12 healthy controls)  [7, 37], 18F-florbetaben
(10 AD, 10 MCI) [19], and 18F-NAV4694 (7 AD, 10 MCI, 25 healthy controls, 3 FTLD patients) [9**]. m: 
region-wise linear slope; r: Pearson correlation coefficient; SUVR: Standardized Uptake Value Ratio; BP:
Binding Potential; Dash: not reported.
with cerebellum as reference have been reported for 18F-flutemetamol (1.5, S.D. 0.7) [10], 18F-florbetapir
(2.40, S.D. 1.41) [11], 18F-florbetaben (6.2, range 0.6-12.2) [12] and 18F-NAV4694 (7.5, S.D. 6.5) [13]. Fleisch’
κ has been reported for 18F-flutemetamol (0.86-0.96) [10, 14**]), 11C-PIB (0.90) [15], 18F-florbetapir (0.58-
0.76) [11, 16**] and 18F-florbetaben (0.60 [17]; 0.89-0.94 [18]). Cohen’s effect sizes to discriminate AD
from healthy controls vary from study to study, even for the same compounds, ranging between 1.3 and 3.8
[15, 17, 12, 19, 9**, 18]. So far no published studies are available that have directly compared performance
between 18F-amyloid ligands within the same subjects in vivo which would be highly informative for the clinician.
3 Validation against neuropathology
In a clinical context, generally nuclear medicine physicians will read the scans in terms of a positive, a negative
or an indeterminate scan with regards to the presence of Aβ [20**]. Regions of known predilection of increased
ligand retention that have a high diagnostic weight are the precuneus and posterior cingulate, lateral temporal
cortex and orbitofrontal cortex, and also the ventral striatum [21*] (Fig. 1). Binary visual reads predict the
presence of neuritic amyloid plaques with high sensitivity (96%) and specificity (100%) according to the 18F-
florbetapir phase 3 trial [22**]. Amyloid ligand retention correlates with immunohistochemical measures of
amyloid plaque surface area [22**, 14**].
Academic clinicopathological case reports defined false-positives and false-negatives based on conventional
neuropathological nosological diagnoses rather than a newly developed binarized neuritic plaque score [2, 4]. A
positive 11C-PIB scan can occur with a neuropathological diagnosis of Lewy-body disease rather than Alzheimer’s
disease when diffuse plaques are abundant (e.g. [23**]). This has also been described in one cognitively
intact control [24*]. Two false-negative cases compared to conventional neuropathological standards have been
reported [25**, 24*]. The prespecified regions sampled according to CERAD criteria do not fully coincide with
5Figure 1: Representative positive and negative scan. A. 18F-flutemetamol scan, obtained in a clinically probable 
AD case, with a positive visual read. B. 18F-flutemetamol scan, obtained in a cognitively intact healthy volunteer, 
with a negative visual read. C. Voxels with the highest feature weight for discriminating between clinically probable
AD and healthy controls.
the regions of predilection for increased amyloid ligand retention. Another explanation for a false-negative scan
may be the occurrence of ’PIB-refractory’ amyloid plaques for yet unknown reasons. A special instance of such
refractoriness is AD due to the Arctic Amyloid Precursor Protein mutation [26]. Overall, given the high accuracy
obtained in large-scale clinicopathological series, the occurrence of false-positives and false-negatives is probably
a relatively rare event except for Lewy body cases exhibiting high amounts of diffuse plaques [23**].
4 Amyloid imaging versus other technical investigations in clinical use
In order to define the role of amyloid imaging in clinical practice, it is important to position it with respect to
other technical investigations in clinical use and define to which degree it would replace these investigations or
provide complementary information.
4.1 Amyloid imaging and structural MRI
The sensitivity for discriminating between clinically probable AD and controls is similar for amyloid PET and
structural magnetic resonance imaging (MRI) according to a supervised machine learning analysis of the 18F-
flutemetamol phase 2 data [21*]. Specificity, however, is significantly lower for the MRI gray matter maps
than for 18F-flutemetamol PET (68% as opposed to 92%) [21*], probably because there is substantial overlap
in hippocampal volume loss between normal aging and AD patients [27, 28**]. According to a population-
based study (mean age 78 years), 40% of cognitively intact individuals show patterns of MRI volume loss or
FDG hypometabolism corresponding to what is seen in Alzheimer’s disease [29**]. Only 40% of these had an
abnormal amyloid PET scan [29**, 30**].
4.2 Amyloid PET versus FDG PET
Visual readings of 11C-PIB scans have a higher sensitivity and specificity than fluorodeoxyglucose-PET (FDG-
PET) to discriminate clinically probable AD cases from healthy controls [34]. In the discrimination of clinically
probable AD from clinically probable FTLD, accuracy is comparable, but 11C-PIB has a higher sensitivity but
specificity can be lower depending on the age range of included subjects [35]. Moreover, interrater agreement of
the visual reads is higher for 11C-PIB (Fleiss κ 0.96) than for FDG-PET (Fleiss κ 0.72) [35]. In atypical variants
of AD (such as posterior cortical atrophy or the logopenic variant of AD), the topography of hypometabolism
reflects the clinical phenotype while the distribution of amyloid ligand retention does not [31, 7, 32*], in
accordance with what one would expect based on neuropathology [33**] (Fig. 2).
4.3 Amyloid imaging versus CSF
Dichotomization based on 11C-PIB is highly concordant with that based on cerebrospinal fluid (CSF) Aβ42
[36]. When 18F-florbetapir and CSF Aβ42[37] were compared, discordance occurred more frequently [37]. The
relative place of amyloid PET versus CSF Aβ42 in a diagnostic algorithm remains one of the questions to be
resolved. An advantage of amyloid PET may be the high test-retest reliability and between-centre comparability
of cut-offs and interpretation [38*] compared to CSF.
5 Changes in clinical-diagnostic thinking
According to a pioneering investigator-driven clinical utility study [39**] the referring clinician changed his/her
diagnosis in 23% of cases following FDG- and amyloid PET combined, principally based on the amyloid PET
findings, d emonstrating t he a dded d iagnostic v alue o f a myloid i maging i n a  r ealistic s etting e ven w ithin a
clinically highly experienced and dedicated Alzheimer centre [39**]. An industry-sponsored prospective study
[40**] came to similar conclusions. Even in diagnostic trials where the binary read constitutes the primary study
outcome, the proportion of false-positive clinical AD diagnosis at study entry has been high (37%) [16**]. Similar
discrepancies between the clinical diagnosis at entry and the amyloid scan have been reported in therapeutic phase
3  trials  evaluating  amyloid-lowering  drugs,  in  particular  in APOEǫ4 noncarriers, and in the Alzheimer’s Disease
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Figure 2: Schematic view of how clinical phenotypes, lesion topography and neuropathological hallmark
lesions relate to each other [44]. The clinical phenotype stands in a relatively direct one-to-one relationship to the
topography. In vivo measures that are situated at the level of the topographical distribution of the pathology are
neuropsychology, structural MRI, and FDG-PET. However, the relationship between the topography and the
underlying neuropathological hallmark lesions is probabilistic, meaning that the regional predilection of specific lesion
types is a matter of probability, with significant inter-individual variation. Measures that are more closely related to
the underlying neuropathological hallmark lesions are currently restricted to CSF measures of Aβ42 and phosphotau, 
and amyloid imaging. This is a schematic view, some neuropathological hallmark lesions are not shown such as Lewy
bodies, and the relationship between the hallmark lesions and the topography is of a complexity that cannot be
adequately summarized in this type of scheme.
Neuroimaging Initiative (ADNI) observational cohort, in which 77% of AD patients had a positive
18F-florbetapir scan [41].
One of the main methodological caveats in industry-sponsored trials of clinical utility [42, 40**] is to avoid
bias in favor of a positive study outcome due to the partially subjective evaluations by physicians in terms of
pre- and post-scan diagnosis, impact on disease management or confidence rating and the relatively unblinded
nature of the primary outcome evaluation in studies conducted until now [42, 40**].
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6 Clinical scenarios encountered in a memory clinic in relationship to the
potential utility of amyloid imaging or lack thereof
Schematically, one could envisage two radically different approaches: to apply amyloid imaging in a limited
subset of patients who according to dementia experts fulfill well-delineated criteria, or, alternatively, to divulge
the technique at the different healthcare levels where the diagnostic gain would be largest at those levels where
diagnostic accuracy currently is lowest. The latter approach however has to take into account the relatively
frequent occurrence of positive scans even in the absence of cognitive complaint [29**, 41, 43*]. In a healthcare
system that wishes to provide equal access to state-of-the-art medical resources for all citizens, the first option,
i.e. restricted use if clinical expert diagnosis and a conventional approach (e.g. using structural imaging) lack
accuracy, would probably be the only affordable option. The main factors on which this judgment will be based
are the a priori probability of AD prior to the scan and the value attached to the increase in diagnostic utility in
the context of (currently limited) therapeutic options.
6.1 Age-dependence of the clinical utility of amyloid imaging
In early-onset dementia (defined here restrictively as dementia with onset below the age of 60), fronto-temporal
lobar degeneration (FTLD) is as frequent as AD as a cause of dementia. Non-AD lesions that have a topographic
distribution similar to Alzheimer’s pathology may cause a clinical phenotype similar to the typical amnestic
syndrome seen in clinically probable AD [44, 45**]. A diagnosis may have a significant impact at the personal
and familial emotional and relational level as well as at the level of third-party payers. An accurate diagnosis
may also guide the search for a genetic cause. Treatment options and clinical/behavioral progression to be
expected over the disease course also differ between AD and FTLD. The prevalence of a positive amyloid scan
below the age of 60 years in the absence of clinical symptoms is very low so that a positive scan is more likely
to be related to the clinical symptoms compared to the older age group.
At the other end of the age spectrum, a third of cognitively intact subjects above the age of 78 [29**, 41]
have a positive amyloid scan, and 50% above the age of 82 [43*]. As a consequence, the specificity in terms
of a clinical disease diagnosis necessarily will be relatively lower in this age group. This does not mean that the
positive scan is irrelevant: cognitively intact amyloid-positive subjects show more cognitve decline during up to
10 years preceding the scan than amyloid-negative subjects, even when matched for Apolipoprotein E ε4 status
[46**].
6.2 Focal non-amnestic syndromes caused by neurodegenerative disease
In a memory clinic the focal non-amnestic syndromes mainly refer to primary progressive aphasia (with three
variants), posterior cortical atrophy (PCA), corticobasal syndrome (CBS) and comportmental disorder (fron-
totemporal dementia behavioral variant (bvFTD)). For some of these focal non-amnestic syndromes, in particular
CBS and PPA, it may be hard to reliably predict on clinical grounds what the underlying neuropathology will
be, Alzheimer’s disease or FTLD [47]. Detailed neurolinguistic phenotyping allows to estimate the probability of
AD as an underlying cause of PPA but requires neurolinguistic expertise [48], in particular at the initial stages
of the diseaes [49*].
6.3 High cerebrovascular load on MRI
In an amyloid imaging study of subcortical vascular disease, approximately one third of cases were 11C-PIB 
positive [50]. The amount  of  white  matter  hyperintensities correlates with 11C-PIB based measures of Aβ load in
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6.4 Clinical diagnosis of probable or possible Lewy body disease
In an amyloid imaging study, 11 out of 13 clinically probable Lewy body dementia (DLBD) patients had a
positive 11C-PIB scan [53], compared to only 2 out of 12 patients with Parkinson’s disease with dementia. This
has been confirmed by other studies using 18F-ligands [12]. Therefore, usefulness in DLBD is probably limited
since a number of cases have a positive amyloid scan despite the absence of neuritic plaques [23**].
6.5 Prediction in MCI
A positive amyloid scan in a patient with mild cognitive impairment (MCI) has predictive value for future
cognitive decline with a 5-year conversion sensitivity of 85-93% and specificity between 81-100% [16**, 41,
38*, 21*]. In Alzheimer’s Disease Neuroimaging Initiative (ADNI), the prevalence of a positive amyloid scan
in early MCI patients is 43% and in late MCI patients 62% [41]. As long as there is no proven therapy in the
predementia stage of AD, the diagnosis of amyloid-positivity in a case with MCI will prolong the phase during
which a subject has to live with a diagnosis of prodromal AD/MCI due to AD. The time course of decline is
currently hard to predict at the individual level. The effect of disclosing a positive or negative amyloid scan
result in MCI patients in clinical practice is an important topic for future research.
6.6 Healthy controls
In AD mutation carriers, a gradual increase in amyloid ligand retention occurs years before clinical symptoms
according to cross-sectional studies [54**, 55**]. Indirect evidence suggests that it may take approximately 15
patients with clinically probable cerebral amyloid angiopathy (CAA) but not in AD [51]. Based on the amyloid
scan it may be impossible to distinguish between CAA and AD [52].
years to evolve from a clearly negative amyloid scan to a plateau level [56**]. The amyloid increase probably
continues into the MCI stage to level off prior to the dementia stage [57].
With our current knowledge we are not able to reliably predict on the basis of the amyloid scan alone at
the individual level which cognitively intact individual will deteriorate cognitively or when [30**]. Due to this
uncertainty and also given the absence of any proven intervention to ward off future decline, amyloid scanning
is not indicated outside a research context in healthy volunteers [20**, 58*].
6.7 Summary
Based on the above considerations, we discern 4 situations where amyloid PET as biomarker evidence may
contribute to the differential diagnostic process in a way that is relevant for the patient and the caregivers
concerned [59*] (Fig. 3):
1. Early-onset dementia (onset before 60 years of age), in the absence of a known genetic mutation in the
family
2. Focal cortical syndromes: PPA and CBS
3. The presence of comorbidity that could explain the cognitive decline, i.e. high vascular load on structural
MRI, long-standing psychiatric history, medical comorbidity.
4. Rapidly progressive cognitive deterioration
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7 Conclusion
Currently the validity of amyloid PET for detecting the presence of moderate to severe amounts of neuritic
and diffuse plaques appears to be convincingly demonstrated, also for the new 18F-ligands. Studies of clinical
utility however are only emerging. Among the most critical questions for near future empirical research in this
context are the benefit of disclosure of a positive or negative amyloid scan in MCI patients in clinical practice,
the comparison of clinical utility between amyloid PET and CSF AD biomarker analysis, and the efficacy of
amyloid imaging in terms of patient outcome.
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Figure 3: Clinical utility of amyloid imaging. Proposed clinical algorithm for the utility of amyloid imaging
in patients presenting at a memory clinic with a cognitive deficit that is confirmed by clinical assessment of
cognitive functions or by neuropsychological evaluation. This algorithm is tentative and subject to further
empirical evaluation.
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3. Current algorithms take a restrictive approach to the use of amyloid imaging and delineate specific
circumstances where amyloid imaging is indicated.
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